PKC ISOZYME-SELECTIVE MODULATORS FROM THE INDOLACTAMS

Information

  • Research Project
  • 3507954
  • ApplicationId
    3507954
  • Core Project Number
    R44GM042285
  • Full Project Number
    2R44GM042285-02
  • Serial Number
    42285
  • FOA Number
  • Sub Project Id
  • Project Start Date
    3/1/1992 - 32 years ago
  • Project End Date
    2/28/1993 - 31 years ago
  • Program Officer Name
  • Budget Start Date
    3/1/1992 - 32 years ago
  • Budget End Date
    2/28/1993 - 31 years ago
  • Fiscal Year
    1992
  • Support Year
    2
  • Suffix
  • Award Notice Date
    2/14/1992 - 33 years ago

PKC ISOZYME-SELECTIVE MODULATORS FROM THE INDOLACTAMS

Protein kinase C (PKC) is a family of isozymes which plays a crucial role in signal transduction for a variety of biologically active substances which activate cellular functions and proliferation. The ability to selectively modulate the members of this family offers the opportunity for the development of tools for the investigation of many cellular processes as well as for the development of new pharmaceuticals for the treatment of diseases such as cancer, AIDS, cardiovascular diseases, and diseases, and diseases of the CNS and immune system. The proposed project will apply to the indolactam class, techniques and information which have been successfully applied by the applicant to the development of PKC isozyme-selective modulators in other classes of "phorboids". Thus, a series of carefully planned analogs and derivatives of indolactam V will be prepared by total synthesis and evaluated for isotype-selective binding using a broad panel of rDNA-derived PKC isozymes. The SAR information obtained during this study will be integrated into a model of the functioning of the regulatory sites of the PKC isozymes. Selective modulators from the initial screen will be further tested for agonist/antagonist properties in the PKC isozymes and in functional assays including: anti-cancer, anti-HIV and platelet functions.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R44
  • Administering IC
    GM
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SSS
  • Study Section Name
  • Organization Name
    PROCYON PHARMACEUTICALS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    WOBURN
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    01801
  • Organization District
    UNITED STATES